ClinicalTrials.gg

Program

Spironolactone

Also written as “Spironolactone Oral Suspension”, “Torsemide and Spironolactone tablet” and “Torsemide Tablets and Spironolactone Tablets”.

Its studies are mostly in Fibrosis · Heart Failure, led by 5 companies.

Furthest: phase 4, since Aug 28, 20237 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CMP Development21 open or runningphase 4since Aug 28, 2023Feb 16, 2019Jun 2028phase 4 · NCT06021860
Sarfez Pharmaceuticals20 open or runningphase 3since Jun 3, 2025Jun 3, 2025none ahead
Orion Corporation, Orion Pharma10 open or runningphase 1since Mar 8, 2010Mar 8, 2010none ahead
Pfizer10 open or runningphase 1since Jan 2, 2024Jan 2, 2024none ahead
SPH Sine Pharmaceutical Laboratories10 open or runningphase 1since Aug 26, 2024Aug 26, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2010First study: phase 1 study in HealthyNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT01083290 · 14 enrolled · India
  2. Feb 16, 2019CMP Development's first study: phase 1 study in Drug Drug InteractionNew to CMP DevelopmentCMP Development · NCT03909529 · 28 enrolled · India
  3. Aug 28, 2023Phase 4 study in FibrosisCMP Development · NCT06021860 · 96 planned
  4. Jan 2, 2024Pfizer's first study: phase 1 study in Healthy ParticipantsNew to PfizerPfizer · NCT06205407 · 42 enrolled · United States
  5. Aug 26, 2024SPH Sine Pharmaceutical Laboratories's first study: phase 1 study in Bioequivalence StudyNew to SPH Sine Pharmaceutical LaboratoriesSPH Sine Pharmaceutical Laboratories · NCT06579053 · 64 enrolled · China
  6. Jun 3, 2025Sarfez Pharmaceuticals's first studies: 2 phase 3 studiesNew to Sarfez PharmaceuticalsSarfez Pharmaceuticals · NCT07015671, NCT07046975

Ahead

  1. Jun 2028Primary completion: phase 4 study in FibrosisCMP Development · NCT06021860

TargetBeta

NR3C2 →read by rule
“Mineralocorticoid receptor antagonist”ChEMBL 37, by rule

Other programs on NR3C2

ProgramCompanyFurthest phaseStudies
finerenoneruleBayerphase 425
drospirenoneruleestetraphase 420
vamorolonerulereveragen-biopharma-incphase 411
balcinrenoneruleAstraZenecaphase 315
HRS-1780Jiangsu HengRui Medicinephase 37

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07046975Bioavailability Heathy Volunteers · United States3CompletedSarfez PharmaceuticalsFeb 28, 202624
NCT07015671Bioequivalence Study in Healthy Subjects · United States3CompletedSarfez PharmaceuticalsDec 30, 202524
NCT06579053Bioequivalence Study · China1CompletedSPH Sine Pharmaceutical LaboratoriesMay 5, 202364
NCT06205407Healthy Participants · United States1CompletedPfizerMar 1, 202442
NCT06021860Fibrosis4Not yet recruitingCMP DevelopmentJun 202896
NCT03909529Drug Drug Interaction · India1CompletedCMP DevelopmentApr 19, 201928
NCT01083290Healthy · India1CompletedOrion Corporation, Orion PharmaApr 201014

How it is read

Names in the registry

  • “Spironolactone”, 4 entries
  • “Spironolactone Oral Suspension”, 1 entry
  • “Torsemide and Spironolactone tablet”, 1 entry
  • “Torsemide Tablets and Spironolactone Tablets”, 1 entry
  • “25 mg Aldactone (Spironolactone) tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.